Skip to main content
PharmaSGP Holding SE logo

PharmaSGP Holding SE — Investor Relations & Filings

Ticker · PSG ISIN · DE000A2P4LJ5 LEI · 3912005CZ12PVVCIPT91 F Manufacturing
Open in API
Filings indexed 199 across all filing types
Latest filing 2025-07-23 Declaration of Voting R…
Country DE Germany
Listing F PSG

About PharmaSGP Holding SE

https://pharmasgp.com/english/

PharmaSGP Holding SE is a pharmaceutical company specializing in the development and marketing of a broad portfolio of over-the-counter (OTC) drugs and other healthcare products. The company focuses on pharmacy-exclusive products for chronic indications, primarily utilizing natural active ingredients with a favorable side-effect profile. It holds a market-leading position in several therapeutic areas, particularly in systemic, chemical-free pain remedies with its RubaXX® (rheumatic pain) and Restaxil® (nerve pain) brand families. The portfolio also includes prominent brands such as Baldriparan® (natural sleep aid), Formigran® (migraine), Spalt® (general pain), and DESEO® and NERADIN® (sexual weakness).

Recent filings

Filing Released Lang Actions
Declaration of Voting Results & Voting Rights Announcements 2025
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled 'Voting rights Announcements' and explicitly states 'Notification of Major Holdings' under German securities law (WpHG). It details the acquisition/disposal of shares with voting rights by Madlena Hohlefelder and associated entities, crossing specific percentage thresholds (e.g., moving from 77.82% to 91.12%). This content directly corresponds to regulatory filings concerning changes in significant share ownership, which maps precisely to the 'Major Shareholding Notification' category (MRQ). Although it is a regulatory announcement, MRQ is a more specific classification than the general 'RNS' fallback.
2025-07-23 English
PharmaSGP Holding SE: FUTRUE GmbH, Tender of a total of 540 shares in PharmaSGP Holding SE in a delisting tender offer by the reporting date of the announcement published on July 21, 2025, pursuant to
Director's Dealing Classification · 100% confidence The document is explicitly titled 'Directors’ Dealings' and contains a 'Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them'. It details a transaction (Tender of shares) made by an individual closely associated with a member of the administrative body (Dr. Clemens Fischer). This directly matches the definition for Director's Dealing (DIRS). The document is not a general earnings release, annual report, or a proxy statement.
2025-07-23 English
PharmaSGP Holding SE: Acceptance period for FUTRUE GmbHs public delisting tender offer underway
Delisting Announcement Classification · 100% confidence The document explicitly announces that the 'Acceptance period for FUTRUE GmbH’s public delisting tender offer [is] underway'. This directly relates to the process of a company's stock being removed from an exchange following a tender offer. The key phrase is 'public delisting tender offer'. This aligns perfectly with the definition for Delisting Announcement (DLST). Although it is an announcement, the core subject matter is the delisting event itself, making DLST more specific than a general RPA or RNS.
2025-07-18 English
PharmaSGP Holding SE adjusts its revenues forecast for the full year 2025
Earnings Release Classification · 100% confidence The document is an 'Ad-hoc' announcement dated July 11, 2025, disclosing an 'inside information' event under Article 17 of Regulation (EU) No 596/2014 (MAR). The core content is the adjustment of the revenue forecast for the full year 2025. This type of announcement, which communicates a material change in financial outlook outside of a scheduled earnings release or annual report, is best classified as a general Regulatory Filing (RNS) or potentially an Earnings Release (ER) if it were the primary results announcement. However, since it is specifically a forecast *adjustment* disclosed via an EU regulation (MAR) and distributed by EQS News, it fits the broad 'Regulatory Filings' category (RNS) as it is a mandatory, non-periodic disclosure. It is not a full report (10-K, IR), a presentation (IP), or a management discussion (MDA). Given the options, RNS is the most appropriate fallback for mandatory, ad-hoc regulatory disclosures that aren't explicitly covered elsewhere. FY 2025
2025-07-11 English
PharmaSGP Holding SE holds 2025 Annual General Meeting
AGM Information Classification · 100% confidence The document explicitly states in the title and body: 'PharmaSGP Holding SE holds 2025 Annual General Meeting'. It details the proceedings, including shareholder representation (91.12%), dividend resolutions (€0.05 minimum dividend approved), and management reports on 2024 performance and 2025 forecasts. This content directly corresponds to the materials and announcements related to an Annual General Meeting (AGM). Therefore, the classification is AGM-R.
2025-06-26 English
PharmaSGP SE plans to redeem own shares conditions for squeeze-out under conversion law are met
Transaction in Own Shares Classification · 99% confidence The document is a short corporate announcement (4738 characters) released via EQS News. The headline and content explicitly state that "PharmaSGP SE plans to redeem own shares" and discusses the conditions for a squeeze-out, which relates to changes in share capital structure and ownership resulting from share buybacks/redemptions. This directly aligns with the definition of 'Transaction in Own Shares' (POS), which covers share repurchase/issuance, or potentially 'Share Issue/Capital Change' (SHA). Since the primary action described is the redemption/retirement of treasury shares (a form of share repurchase/cancellation), POS is the most specific fit. It is not a full report (10-K, IR) nor a general announcement of a report (RPA/RNS), but a specific corporate action disclosure.
2025-06-18 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.